HAS2 and cancer: We analyzed the in vitro effects of the direct FXa inhibitor Apixaban on proliferation, mortality, cell migration, expression of key transcription factors (p16, p21 and p53) and HAS2, and MMPs in the following 5 cancer cell lines: OVCAR3 (highly aggressive ovarian cancer cells), MDA MB 231 (highly aggressive breast cancer cells), CaCO-2 (highly aggressive colon cancer), LNCaP (highly aggressive prostate cancer) and U937 (from histiocytic lymphoma).